Heme (Fe-protoporphyrin IX) (Fe-PPIX)

Heme (Fe-protoporphyrin IX) is a vital chemical entity in the life cycle of Plasmodium parasites, serving as the primary activator for artemisinin-class antimalarial drugs. During the parasite's intraerythrocytic stage, it digests host hemoglobin within its food vacuole, releasing free heme as a toxic byproduct (Klonis et al., 2011, PMID: 21730148). Artemisinin and its derivatives exploit this environment by reacting with the iron center of heme, which facilitates the reductive cleavage of the drug's characteristic endoperoxide bridge. This chemical reaction generates highly reactive free radicals and electrophilic species that cause widespread oxidative damage and alkylation of parasite proteins, lipids, and membranes (O'Neill et al., 2010, PMID: 20336043). By utilizing the parasite's own metabolic byproduct as a trigger, artemisinins achieve potent and rapid-acting parasiticidal effects. Consequently, heme acts as both a catalyst for drug activation and a mediator of the drug's lethal effects against malaria. This unique mechanism distinguishes artemisinins from other antimalarials that primarily target the crystallization of heme into hemozoin. Understanding this interaction is crucial for addressing emerging resistance patterns linked to altered parasite stress responses.

Other names

Ferriprotoporphyrin IXFPHematinProtohemeIron-protoporphyrin IXHeme b

Artemisinin-based drugs undergo reductive cleavage of their internal 1,2,4-trioxane endoperoxide bridge upon interaction with Fe(II)-heme, generating reactive carbon-centered radicals that alkylate and damage essential parasite proteins and lipids (Wang et al., 2019, PMID: 31104844).